Irinotecan Liposomes in Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

360

Participants

Timeline

Start Date

July 20, 2025

Primary Completion Date

April 1, 2028

Study Completion Date

July 1, 2030

Conditions

Locally Advanced Rectal Cancer

Interventions

DRUG

NALIRI

Irinotecan liposomes

RADIATION

LCRT

Long-course concurrent chemoradiotherapy

DRUG

FOLFOX

Fluorouracil/Leucovorin, Oxaliplatin (5-FU/LV, OX)

Trial Locations (1)

Zhejiang Cancer Hospital, Hangzhou

All Listed Sponsors

lead

Zhejiang Cancer Hospital

OTHER